Integrative oncology: The last ten years - A personal retrospectve

Alternative Therapies in Health and Medicine

Volumn 13, Issue 1, 2007, Pages 56-64

  Boyd, D Barry ^a,b  

^a YALE NEW HAVEN HEALTH SYSTEM   (United States)

^b Boyd Center for Integrative Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE MEDICINE; CANCER CENTER; CANCER EPIDEMIOLOGY; CANCER PATIENT; HUMAN; INTEGRATIVE MEDICINE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL PRACTICE; MEDICAL SPECIALIST; NUTRITION; ONCOLOGY; PERSONAL EXPERIENCE; REVIEW;

ATTITUDE OF HEALTH PERSONNEL; COMPLEMENTARY THERAPIES; DELIVERY OF HEALTH CARE, INTEGRATED; DIET THERAPY; DIETARY SUPPLEMENTS; HEALTH BEHAVIOR; HUMANS; LIFE STYLE; MEDICAL ONCOLOGY; NEOPLASMS; STRESS, PSYCHOLOGICAL;

EID: 33846223880     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Lerner MA. Choices in Healing: Integrating the Best of Conventional and Complementary Approaches to Cancer. Cambridge, Mass: MIT Press; 1996.
2. Howe GR, Friedenreich CM, Jain M, Miller AB. A cohort study of fat intake and risk of breast cancer. J Natl Cancer Inst. 1991;83(5):336-340.
3. Steinmertz KA, Kushi LH, Bostick RM, Folsom AR, Potter JD. Vegetables, fruit and colon cancer in the Iowa Women's Health Study. Am J Epidemiol. 1994;139(1):1-15.
4. Le Marchand L, Hankin JH, Kolonel LN, Beecher GR, Wilkens LR, Zhao LP. Intake of specific carotenoids and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 1993;2(3):183-187.
5. Shibata A, Paganini-Hill A, Ross RK, Henderson BE. Intake of vegetables, fruits, beta-carotene, vitamin C and vitamin supplements and cancer incidence among the elderly: a prospective study. Br J Cancer. 1992;66(4):673-679.
6. Kritchevsky D. Dietary fiber and cancer. Nutr Cancer. 1984;6(4):213-219.
7. Slattery ML, Potter JD, Coates A, et al. Plant foods and colon cancer, an assessment of specific foods and their related nutrients (United States). Cancer Causes Control. 1997;8(4):575-590.
8. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trail. J Natl Cancer Inst. 1996;88(21):1550-1559.
9. Albanes D, Heinonen OP, Taylor PR, et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst. 1996;88(21):1560-1570.
10. Asano T, McLeod RS. Dietary fiber for the prevention of colorectal adenomas and carcinomas. Cochrane Database Syst Rev. 2002;(2)CD003430.
11. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med. 2000;342(16):1149-1155.
12. Tornwall ME, Virtamo J, Korhonen PA, et al. Effect of alpha-tocopherol and beta-carotene supplementation on coronary heart disease during the 6-year post-trial follow-up in the ATBC study. Eur Heart J. 2004;25(13):1171- 1178.
13. Bairati I, Meyer F, Gelinas M, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst. 2005;97(7):481-488.
14. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: The Women's Health Study: a randomized controlled trail. JAMA. 2005;294(1):56-65.
15. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA 2001;285(6):769-776.
16. McCullough ML, Robertson AS, Chao A, et al. A prospective study of whole grains, fruits, vegetables and colon cancer risk. Cancer Causes Control. 2003;14(10):959-970.
17. Giovannucci E, Rimm EB, Liu Y, et al. A prospective study of cruciferous vegetables and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(12):1403-1409.
18. Boyd DB. Insulin and cancer. Integr Cancer Ther. 2003;2(4):315-320.
19. Meyskens FI Jr, Szabo E. Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol Biomarkers Prev. 2005;14(6):1366-1369.
20. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst. 2002; 94(5):391-398.
21. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276(24):1957-1963.
22. Doll R, Peto RT. The cause of cancer, quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981;66(6):1191-1308.
23. Oberley LW. Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed Pharmacother. 2005;59(4):143-148.
24. Li H, Kantoff PW, Giovannucci E, et al. Manganese superoxide dismutase polymorphism, prediagnositc antioxidant status, and risk of clinical significant prostate cancer. Cancer Res. 2005;65(6):2498-2504.
25. Ambrosone CB, Freudenheim JL, Thompson PA, et al. Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res. 1999;59(3);602-606.
26. Schernthaner GH, Schernthaner G. Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention. Scand J Clin Lab Invest Suppl. 2005;240:30-40.
27. Calle EE, Rodriquez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348(17):1625-1638.
28. Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-1 rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat. 1999;56(1):1-10.
29. Kanter-Lewensohn L, Girnita L, Girnita A, et al. Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (1GF-1) pathway. Mol Cell Endocrinol. 2000;165(1-2):131-137.
30. Lu Y, Zi X, Zhoa Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to transtuzumab (Herceptin). J Natl Cancer Inst. 2001;93(24):1852-1857.
31. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20(1):42-51.
32. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
33. Chlebowski RT, Blackburn GL, Elashoff RE, et al. Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women's Intervention Nutrition Study (WINS) [Abstract 10]. Proc Am Soc Clin Oncol. 2005;23(16S):10.
34. Holmes MD, Chen WY, Feskasnich D, et al. Physical activity and survival after breast cancer diagnosis. JAMA. 2005;293(20):2479-2486.
35. Meyerhardt JA, Giovannucci, EL, Holmes, MD, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol. 2006;24:3527-3534.
36. Meyerhardt, JA, Heseltine D, Niedzwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Cin Oncol. 2006;24(22):3535-3541.
37. Xiao C, Ghosh S. NF-kappaB, an evolutionarily conserved mediator of immune and inflammatory responses. Adv Exp Med Biol. 2005;560:41-45.
38. Li Q, Withoff S, Verma IM. Inflammation-associated cancer: NF-kappa B is the lynchpin. Trends Immunol. 2005;26(6):318-325.
39. Pillarisetti S, Saxena U. Role of oxidative stress and inflammation in the origin of Type 2 diabetes-a paradigm shift. Expert Opin Ther Targets. 2004;8(5):401-408.
40. Nakanishi C, Toi M. Nuclear factor-kappa B inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5(4):297-309.
41. Sarkar FH, Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res. 2006;66(7):3347-3350.
42. Hirata T, Ogawa E, Takenaka K, Kawashita F. Suppression of postoperative systemic inflammatory response syndrome with clarithromycin following lung cancer surgery. Eur Surg Res. 2004;36(1):13-19.
43. Sakamoto M, Mikasa K, Majima T, et al. Anti-cachectic effect of clarithromycin for patients with unresectable non-small cell lung cancer. Chemotherapy. 2001;47(6):444-451.
44. Sasaki M, Ito T, Kashima M, Fukui S, Izumiyama N, et al. Erythromycin and clarithromycin modulation of growth factor-induced expression of heparanase mRNA on human lung cancer cells in vitro. Mediators Inflamm. 2001;10(5):259-267.
45. Hamada K, Mikasa K, Yunou Y, Kurioka T, Majima T, Narita N, Kita E. Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. Chemotherapy. 2000;46(1):49-61.
46. Ieshiro R, Goto G, Ota T, Yuasa K, Iguchi M, Okamura J. Effect of clarithromycin in extending the life expectancy of patients with non-small-cell lung cancer-the second report. Jpn J Antibiot. 1998;51(Suppl A):47-49.
47. Mikasa K, Sawaki M, Kita E, et al. Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin. Chemotherapy. 1997;43(4):288-296.
48. Wallwork B, Coman W, Mackay-Sim A, Cervin A. Effect of clarithromycin on nuclear factor-kappa B and transforming growth factor-beta in chronic rhinosinusitis. laryngoscope. 2004;114(2):286-290.
49. Ichiyama T, Nishikawa K, Yoshitomi T, Hasegawa T, Matsubara T, Furukawa S. Inhibitory effect of clarithromycin on NF-kappa B activation. Jpn J Antibiot. 2001;54(Suppl C):46-48.
50. Nielsen NR, Zhang ZF, Kristensen TS, Netterstrom B, Schnohr P, Gronbaek M. Self reported stress and risk of breast cancer: a prospective cohort study. BMJ. 2005;331(7516):548.
51. Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989;2(8668):888-891.
52. Cunningham AJ, Edmonds CV, Jenkins GP, Pollack H, Lockwood GA, Warr D. A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. Psychooncology. 1998;7(6):508-517.
53. Morgenstern H, Gellert GA, Walter SD, Ostfeld AM, Siegel BS. The impact of a psychosocial support program on survival with breast cancer: the importance of selection bias in program evaluation. J Chronic Dis. 1984;37(4):273-282.
54. Goodwin PJ, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med. 2001;345(24):1719-1726.
55. Greer S, Watson M. Mental adjustment to cancer: its measurement and prognostic importance. Cancer Surv. 1987;6(3):439-453.
56. Rodgers J, Martin CR, Morse RC, Kendell K, Verrill M. An investigation into the psychometric properties of the Hospital Anxiety and Depression Scale in patients with breast cancer. Health Qual Life Outcomes. 2005;3(1):41-55.
57. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Inst. 2000;92(12):994-1000.
58. Mormont MC, Waterhouse J, Bleuzen P, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2002;6(8):3038-3045.
59. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immuneosurveillance: immunoselection and immunosubversion. Nature Rev Immunol. 2006;6(10):715-727.
60. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking and highly active retroviral therapy. J Natl Cancer Inst. 2005;97(6):425-432.
61. Wang RF. Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer. Semin Cancer Biol. 2006;16(1):73-79.
62. Scadden DT. AIDS-related malignancies. Annu Rev Med. 2003;54:285-303.
63. Trofe J, Beebe TM, Buell JF, et al. Posttransplant malignancy. Prog Transplant. 2004;14(3):193-200.
64. Stewart T, Tsai SC, Grayson H, Henderson R, Opelz G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet. 1995;346(8978):796-798.
65. Lan RY, Ansari AA, Lian ZX, Gershwin ME. Regulatory T cells: development, function and role in autoimmunity. Autoimmun Rev. 2005;4(6):351-363.
66. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151-1164.
67. Wei S, Kryczek I, Zou L, et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 2005;65(12):5020-5026.
68. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005;65(6):2457-2464.
69. Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11(4):1467-1473.
70. Kawaida H, Kono K, Takahashi A, et al. Distribution of CD4+CD25 high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res. 2005;124(1):151-157.
71. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer. 2005;92(5):913-920.
72. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased population of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003;9(12):4408-4408.
73. Woo Ey, Yeh H, Chu CS, et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168(9):4272-4276.
74. Hagemann T, Wilson J, Kulbe H, et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005;175(2):1197-1205.
75. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005;7(5):411-423.
76. Hayakawa Y, Screpanti V, Yagita H, et al. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol. 2004;172(1):123-129.
77. Gilbertson SM, Shah PD, Rowley DA. NK cells suppress the generation of Lyt-2+ cytolytic T cells by suppressing or eliminating dendritic cells. J Immunol. 1986;136(10):3567-3571.
78. Ljung T, Holm G, Friberg P, et al. The activity of the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system in relation to waits/hip circumference ratio in men. Obes Res. 2000;8(7):487-495.
79. Rosmond R, Dalbnan MF, Bjorntorp P. Stress-related Cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab. 1998;83(6):1853-1859.
80. Meisinger C, Heier M, Loewel H; MONICA/KORA Augsburg Cohort Study. Sleep disturbance as a predictor of type 2 diabetes mellitus in men and women from the general population. Diabetologia. 2005;48(2):235-241.
81. Stevens RG. Orcadian disruption and breast cancer: from melatonin to clock genes. Epidemiology. 2005;16(2):254-259.
82. Schernhammer ES, Laden F, Speizer FE, et al. Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst. 2003;95(11):825-828.
83. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses health study. J Natl Cancer Inst. 2001;93(20):1563-1568.
84. Thaker PH, Han LY, Kamat AA, et al Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 2006;12(8):939-944.
85. Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res. 2003;9(12):4514-4521.
86. Kennedy DD, Ladas EJ, Rheingold SR, Blumberg J, Kelly KM. Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy treatment. Pediatr Blood Cancer. 2005;44(4):378-385.
87. Outomuro D. Grana DR, Azzato F, Miliei J. Adriamycin-induced myocardial toxicity: New solutions for an old problem? Int J Cardiol. 2006 Jul 21; [Epub ahead of print].
88. Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy induced peripheral neuropathy: a randomized controlled trial. Neurology. 2005;64(1):26-31.
89. Shimpo K, Nagatsu T, Yamada K, et al. Ascorbic acid and adriamycin toxity. Am J Clin Nutr. 1991;54(6 Suppl):1298S-1301S.
90. Khalsa GS, Bhajan Y. Breathwalk: Breathing Your Way to a Revitalized Body, Mind and Spirit. New York, NY: Broadway Books; 2000.
91. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97(11):2919-2925.
92. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2003;64(4):604-611.
93. Rhodes DR, Chinnaiyan AM. Integrative analysis of the cancer transcriptome. Nat Genet. 2005;37(Suppl):S31-S37.
94. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938-2947.
95. Brewer GJ. Copper lowering therapy with tetrathiomoiybdate as an antiangiogenic strategy in cancer. Curr Cancer Drug Targets. 2005;5(3):195-202.
96. Shaked Y, Emmenegger U, Francia G, et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res. 2005;65(16):7045-7051.
97. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346-2357.
98. Holtl L, Ramoner R, Zelle-Rieser C, et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyciophosphamide. Cancer Immunol Immunother. 2005;54(7):663-670.
99. Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105(7):2862-2868.
100. Dy GK, Bekele L, Hanson LJ, et al. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol. 2004;(23):4810-4815.